TEVA Stock Analysis: Buy, Sell, or Hold?
TEVA - Teva Pharmaceutical Industries Limited American Depositary Shares
$32.83
-0.25 (-0.76%)
▼
5d:
-5.01%
30d:
-7.13%
90d:
-0.24%
HOLD
LOW Confidence
Analysis Updated: Jun 3, 2026 12:00 AM ET
Earnings: Jul 29, 2026
Get Alerted When TEVA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
1 traders called TEVA this week
100% bullish • 0 bearish
100% bullish • 0 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: TEVA shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: TEVA shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$64.66
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$40.15
18.2% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 10.7x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: TEVA is currently trading at $32.83, which is considered oversold relative to its 30-day fair value range of $33.38 to $35.90. The stock's valuation (Forward PE: 10.6) is in line with its historical norms (10.7). Remarkably, the market is currently pricing in an annual earnings decline of 0.4% over the next few years. This pessimistic expectation contrasts with the company's recent 72.2% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, TEVA is showing support break momentum. The price is currently testing key support at $32.37. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $41.27 (+25.7%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, TEVA is showing support break momentum. The price is currently testing key support at $32.37. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $41.27 (+25.7%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$33.38 -
$35.90
Company Quality Score
48/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
79.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 25.7% below Wall St target ($41.27)
- CAUTION: Recommendation downgraded due to -5.0% 5-day decline
Trading Range Analysis
30-Day Trading Range
$33.38 -
$35.90
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$32.37
Resistance Level
$35.47
Current Trend
Support Break
Technical data as of
Jun 3, 2026
Fundamental Context
Forward P/E (Next Year Est.)
10.58
Wall Street Target
$41.27
(+25.7%)
Revenue Growth (YoY)
2.3%
Earnings Growth (YoY)
72.2%
Profit Margin
9.0%
Valuation Discount vs History
-0.4% cheaper
PE vs Historical
10.6 vs 10.7
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-0.4%
(market-implied from PE analysis)
1-Year Target
$32.70
(0%)
2-Year Target
$32.57
(-1%)
3-Year Target
$32.44
(-1%)
3-Yr Target (if PE normalizes)
(PE: 11→11)
$32.81
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.9, Growth: 31.1%)
$153.36
(+367%)
Base:
(SPY PE: 10.6, Growth: 31.1%)
$74.06
(+126%)
Bear:
(PE: 9.0, Growth: 31.1%)
$62.95
(+92%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (26x PE), but valuation improves significantly next year (11x PE) as earnings recover.
Trailing PE: 25.79 | Current EPS (TTM): $1.34
Bull Case
$76.03
(+120%)
Analyst growth 100.0%, PE expands to 28.4
Base Case
$69.12
(+100%)
Market implied 100.0%, PE stable at 25.8
Bear Case
$23.50
(-32%)
Severe decline -20.0%, PE contracts to 21.9
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 10.6 to 10.7
Stabilization Target:
$33.20
(+1.1%)
PE Expansion Potential:
+1.1%
Share & Embed Analysis
Last updated: June 04, 2026 12:43 AM ET
Data refreshes hourly during market hours. Next update: 1:43 AM
Data refreshes hourly during market hours. Next update: 1:43 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is TEVA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
13
Sells
Net
INSIDERS SELLING
Recent Transactions
Mark Sabag
SELL
62102 shares
2026-03-17
Brian Savage
SELL
1127 shares
2026-03-05
Christine Fox
SELL
7924 shares
2026-03-05
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$192 | 66 BUY |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$125 | 60 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$104 | 56 HOLD |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$21 | 58 HOLD |
|
HCM
HUTCHMED DRC |
STRONG BUY
14 analysts |
$23 | 55 HOLD |
